Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia

被引：4
作者：
Schiavetto, Ilaria [1 ]
Pedrazzoli, Paolo [1 ]
Basilico, Vera [1 ]
Siena, Salvatore [1 ]
机构：
[1] Osped Niguarda Ca Granda, IT-20162 Milan, Italy
来源：
CHEMOTHERAPY | 2008年 / 54卷 / 06期
关键词：
iron supplementation; erythropoiesis-stimulating agents; cancer-related anemia;
D O I：
10.1159/000158539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Unresponsiveness to erythropoiesis-stimulating agents is a major limitation to the treatment of chemotherapy-related anemia. This is often related to a disregulation of iron metabolism leading to functional iron deficiency. However, the use of iron supplementation during treatment with erythropoiesis-stimulating agents has not been as rigorously pursued in anemic patients with cancer as it has in chronic kidney disease. In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue. Copyright (C) 2008 S. Karger AG, Basel..
引用
收藏
页码：417 / 420
页数：4
相关论文
共 23 条
  • [1] Anemia of inflammation: the cytokine-hepcidin link
    Andrews, NC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (09) : 1251 - 1253
  • [2] Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial
    Auerbach, M
    Ballard, H
    Trout, JR
    McIlwain, M
    Ackerman, A
    Bahrain, H
    Balan, S
    Barker, L
    Rana, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1301 - 1307
  • [3] Should intravenous iron be the standard of care in oncology?
    Auerbach, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1579 - 1581
  • [4] Clinical update: intravenous iron for anaemia
    Auerbach, Michael
    Ballard, Harold
    Glaspy, John
    [J]. LANCET, 2007, 369 (9572) : 1502 - 1504
  • [5] Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
    Bastit, Laurent
    Vandebroek, An
    Altintas, Sevilay
    Gaede, Bernd
    Pinter, Tamas
    Suto, Tamas S.
    Mossman, Tony W.
    Smith, Kay E.
    Vansteenkiste, Johan F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1611 - 1618
  • [6] Beguin Y, 2002, HAEMATOLOGICA, V87, P1209
  • [7] Beguin Y., 2005, ANAEMIA CANC ESO SCI, V6, P199
  • [8] Besarab A, 2000, J AM SOC NEPHROL, V11, P530, DOI 10.1681/ASN.V113530
  • [9] Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
    Bohlius, Julia
    Wilson, Jayne
    Seidenfeld, Jerome
    Piper, Margaret
    Schwarzer, Guido
    Sandercock, Josie
    Trelle, Sven
    Weingart, Olaf
    Bayliss, Sue
    Djulbegovic, Benjamin
    Bennett, Charles L.
    Langensiepen, Simon
    Hyde, Chris
    Engert, Andreas
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10): : 708 - 714
  • [10] EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update
    Bokemeyer, C.
    Aapro, M. S.
    Courdi, A.
    Foubert, J.
    Link, H.
    Osterborg, A.
    Repetto, L.
    Soubeyran, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (02) : 258 - 270
123